FDA Approves Targeted Rx for Lung Cancer
The U.S. Food and Drug Administration today approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.
Lung Cancer Rx Might Outperform Chemo
When you're sick, you may feel like the immune system is a weak tool for protecting the body. But new evidence is showing how medications might activate the immune system to treat a very serious illness — lung cancer.
Trial on Bristol-Myers Squib Drug Stopped Early
Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer (NSCLC) was stopped early.
FDA Approves Rx for Combo Treatment of Lung Cancer
The US Food and Drug Administration (FDA) has approved a new medication for the treatment of non-small cell lung cancer (NSCLC).
Single Gene Doubled Risk of Lung Cancer
After decades of public health initiatives, it’s no secret that smoking is bad for your health and can ultimately cause lung cancer.
Timing of Chemotherapy for Lung Cancer
Besides the treatment itself, the timing of chemotherapy given to cancer patients can be important to the success of the treatment.
FDA Approves Zykadia for Late-Stage Lung Cancer
The U.S. Food and Drug Administration today granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC).
Lung Cancer Survival in Women Linked to Hormone Therapy
More people die of lung cancer each year than any other kind of cancer. The survival rate among women, however, is better than men — and the reasons aren't exactly clear.
Experimental Rx Helped Lung Cancer Patients Live for Years
Lung cancer is the leading cause of cancer-related death in the US. Advanced lung cancers have spread to other areas of the body and are extremely tough to beat. An experimental therapy may be a game changer.
Lung Cancer Rx Reduced Kidney Function
In 2011, the US Food and Drug Administration fast-tracked the approval of Xalkori (crizotinib) to treat a specific type of non-small cell lung cancer (NSCLC). Since its approval, side effects have been discovered.